ArticleGlobal health action2026
Antibiotic overuse as a modifiable early-life risk factor for non-communicable diseases in sub-Saharan Africa.
Article in Global health action, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early-life antibiotic overuse is a public health concern. In low- and middle-income countries, consumption has surged by 76% since 2000. This trend is particularly acute in sub-Saharan Africa (SSA), where antimicrobial resistance contributes to 255,000 deaths annually and infant antibiotic exposure is widespread in the first two years of life. While a substantial body of research associates antibiotic-induced microbiome disruption with metabolic and immune dysregulation, with large cohorts reporting ~20% higher odds of childhood obesity and asthma, these observational findings do not establish causality and derive largely from high-income settings. This potential pathway remains a policy blind spot within most non-communicable disease (NCD) prevention frameworks. By synthesising biological, epidemiological and implementation evidence, this paper considers early-life antibiotic exposure as a potentially modifiable determinant of lifelong health and outlines a pragmatic research and policy agenda to integrate antibiotic-aware prevention into NCD prevention efforts and routine child health platforms in resource-limited SSA settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.